Study On Effect Of Slidenafil in intrauterine growth restriction

An Observational Study On Effect Of Slidenafil citrate in intra uterine growth restriction

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2019/01/017354

Enrollment

150

Registered

2019-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium Health Condition 2: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium

Interventions

Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: Effective fetal weight less than 10 percentile for gestational age at 28 TO 29 weeks of pregnancy Fetal abdominal circumference less than 5 Percentile for gestational age at 28 TO 29 weeks of pregnancy

Exclusion criteria

Exclusion criteria: Any Kind of fetal malformation Congenital defects in foetus Use of any other vasodilator agent by pregnant mother during the course of study

Design outcomes

Primary

Measure	Time frame
TO compare effective fetal weight , fetal abdominal circumference, umblical artery indices and child birth weight of slidenafil treated group with that of control groupTimepoint: 28-29th 32nd 35th weeks of gestational age, At delivery	—

Secondary

Measure	Time frame
TO compare effective fetal weight , fetal abdominal circumference, umblical artery indices and child birth weight of slidenafil treated group with that of control groupTimepoint: 28-29th 32nd 35th weeks of gestational age, AT delivery	—

Countries

India

Contacts

Public Contactsyed umer farooq

Department of pharmaceutical sciences university of kashmir

gbader2007@gmail.com7006224042

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026